{
    "title": "Possible cancer cure found in blushwood shrub",
    "inventor_name": "Victoria Gordon",
    "publication_year": 2010,
    "device_name": "EBC-46",
    "goal": "Local treatment of solid tumours (cancer) in animals and humans",
    "problem_addressed": "Cancer (solid tumours) with limited effective local therapies",
    "concept_summary": "EBC-46 is a novel small-molecule natural product isolated from the fruit of the Australian blushwood shrub (Blushwood). It is administered by intralesional injection or topical application directly onto a tumour, where it rapidly liquefies and destroys cancer cells with minimal side-effects. The drug has shown rapid tumour knock-down in veterinary patients and is in late pre-clinical development for human use.",
    "detailed_description": "EBC-46 (also called tiglien-3-one derivative EBI-46) is extracted from Fontainea picrosperma (Blushwood) and formulated for local delivery. In veterinary use, a single dose injected into the tumour or applied topically has resulted in tumour liquefaction within 24 hours and complete healing of the site in dogs, cats and horses, with no significant long-term adverse effects. The compound works locally at the site of delivery; systemic efficacy against metastasis has not been demonstrated. QBiotics is conducting veterinary trials and plans to advance to human Phase II trials after regulatory approval. The invention also covers related tiglien-3-one derivatives (EBI-47, EBI-59, etc.) for potential use as anti-cancer, anti-parasitic, antibiotic, or agrochemical agents.",
    "category": "Medical & Dental Technologies",
    "principles": [
        "Targeted local cytotoxicity",
        "Natural product drug discovery",
        "Intralesional injection",
        "Topical drug delivery"
    ],
    "scientific_domains": [
        "Pharmacology",
        "Oncology",
        "Medicinal Chemistry",
        "Natural Products Chemistry"
    ],
    "mechanisms_of_action": [
        "Induction of rapid tumour cell necrosis",
        "Disruption of tumour extracellular matrix",
        "Stimulation of local wound-healing response"
    ],
    "materials": [
        "Blushwood shrub fruit extract",
        "Tiglien-3-one derivative (EBI-46 / EBC-46)",
        "Related tiglien-3-one derivatives (EBI-47, EBI-59, etc.)"
    ],
    "energy_sources": [],
    "inputs": [
        "Solid tumour tissue",
        "Intralesional injection device",
        "Topical formulation"
    ],
    "outputs": [
        "Tumour liquefaction",
        "Tumour destruction",
        "Rapid healing of treatment site",
        "Minimal side-effects"
    ],
    "claimed_performance": "Tumour destruction typically within 24 hours; effective in >100 dogs, cats and horses with no significant long-term adverse effects; rapid healing observed.",
    "experimental_evidence": "Successful treatment of 50 critically ill dogs and about a dozen cats and horses; intralesional injection ablated or palliated advanced tumours in over 100 animals; topical formulation treated ulcerative squamous cell carcinomas in cats and horses; pre-clinical mouse cancer models showed proof-of-concept efficacy.",
    "replication_status": "Veterinary trials ongoing; human clinical trials not yet started but planned for Phase II.",
    "keywords": [
        "EBC-46",
        "Blushwood",
        "Natural product",
        "Cancer therapy",
        "Intralesional injection",
        "Topical anticancer drug",
        "Veterinary oncology",
        "Solid tumours"
    ],
    "related_technologies": [
        "Small-molecule drug discovery",
        "Natural product extraction",
        "Local drug delivery systems"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.6,
    "fringe_score": 0.2,
    "evidence_strength": 0.5,
    "risk_score": 0.3,
    "trl_estimate": 5,
    "source_urls": [
        "http://www.couriermail.com.au/news/queensland/possible-cancer-cure-found-in-blushwood-shrub/story-e6freoof-1225826874057",
        "http://www.ecobiotics.com.au/",
        "http://www.qbiotics.com"
    ],
    "organizations": [
        "EcoBiotics",
        "QBiotics Limited"
    ],
    "applications": [
        "Veterinary treatment of solid tumours",
        "Potential human treatment of skin, breast, colon, prostate and other solid cancers"
    ],
    "limitations": [
        "Only effective when the tumour can be accessed for direct injection or topical application",
        "No demonstrated systemic efficacy against metastatic disease",
        "Human clinical data not yet available",
        "Regulatory approval pending"
    ],
    "open_questions": [
        "Exact molecular mechanism of tumour liquefaction",
        "Efficacy and safety in human patients",
        "Long-term outcomes and potential resistance",
        "Optimal dosing and formulation for different tumour types"
    ],
    "red_flags": [
        "Claims of a \"cure\" without peer-reviewed clinical data",
        "Potential hype in media coverage",
        "Limited publicly available trial data"
    ],
    "evidence_quotes": [
        "The tumour literally liquefies. There is a rapid knock-down of the tumour, it disintegrates within 24 hours and we have a rapid healing response.",
        "EBC-46 has been successful in the local treatment of a range of tumour types in horses, dogs and cats.",
        "In treatment of over 100 dogs, cats and horses, intralesional injection of EBC-46 has successfully ablated or significantly palliated a range of advanced, inoperable tumours ... while causing no significant long-term side effects.",
        "EBC-46 only works locally at the site of delivery and there is no current evidence to suggest that EBC-46 has any systemic efficacy against metastatic disease."
    ]
}